Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
nL-LMNB1-001 for ADLD
NCT06816498Phase 2Active, not recruiting
- Sponsor
- n-Lorem Foundation
- Start
- Mar 2025
- Primary completion
- Mar 2027
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nL-LMNB1-001 in autosomal dominant leukodystrophy with autonomic disease (ADLD), sponsored by n-Lorem Foundation. Primary endpoints: Gait at 24 months, Neurological functioning at 24 months and 1 more. Started Mar 2025; status: active, not recruiting.
02
Drugs
nL-LMNB1-001
03
Conditions
autosomal dominant leukodystrophy with autonomic disease (ADLD)
Beyond the preview
Go deeper on NCT06816498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06816498.